Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Pedro Pablo Guerra Chaviano"'
Autor:
Kirenia Camacho Sosa, Mayra Ramos Suzarte, Carmen Elena Viada González, Elia Nenínger Vinageras, Eduardo Rafael Santiesteban Álvarez, Maurenis Hernández Pérez, Yoanna Ivette Flores Vega, Saylin Alfonso Alemán, Ramón Alberto Ortiz Carrodeguas, Soraida Candida Acosta Brooks, Pedro Pablo Guerra Chaviano, Ivis Mendoza Hernández, Tania Crombet Ramos, Agustín Lage Dávila
Publikováno v:
Revista Cubana de Medicina Militar, Vol 52, Iss 3, Pp e02303004-e02303004 (2023)
Introduction: The response to therapies in advanced lung cancer could be related to certain prognostic factors such as inflammatory indices. Objective: To evaluate the efficacy of the humanized monoclonal antibody nimotuzumab in patients with advance
Externí odkaz:
https://doaj.org/article/e192693e6d24410daf2fcef4ca8c7838
Autor:
Arturo Chang-Monteagudo, Rolando Ochoa-Azze, Yanet Climent-Ruiz, Consuelo Macías-Abraham, Laura Rodríguez-Noda, Carmen Valenzuela-Silva, Belinda Sánchez-Ramírez, Rocmira Perez-Nicado, Tays Hernández-García, Ivette Orosa-Vázquez, Marianniz Díaz-Hernández, María de los Ángeles García-García, Yanet Jerez-Barceló, Yenisey Triana-Marrero, Laura Ruiz-Villegas, Luis Dairon Rodríguez-Prieto, Rinaldo Puga-Gómez, Pedro Pablo Guerra-Chaviano, Yaíma Zúñiga-Rosales, Beatriz Marcheco-Teruel, Mireida Rodríguez-Acosta, Enrique Noa-Romero, Juliet Enríquez-Puertas, Delia Porto-González, Olivia Fernández-Medina, Anet Valdés-Zayas, Guang-Wu Chen, Luís Herrera-Martínez, Yury Valdés-Balbín, Dagmar García-Rivera, Vicente Verez-Bencomo
Publikováno v:
The Lancet Regional Health. Americas, Vol 4, Iss , Pp 100079- (2021)
Background: As a first step towards a vaccine protecting COVID-19 convalescents from reinfection, we evaluated FINLAY-FR-1A vaccine in a clinical trial. Methods: Thirty COVID-19 convalescents aged 22-57 years were studied: convalescents of mild COVID
Externí odkaz:
https://doaj.org/article/54ac04bcc70849c995125a973cce9fdb
Autor:
Vicente Verez-Bencomo, Kalet Leon-Monzon, Yaima Zuniga-Rosales, Yanet Jerez-Barcelo, Yury Valdés-Balbín, Carmen Valenzuela-Silva, Marianniz Diaz-Hernandez, Yanet Climent-Ruiz, Juliet Enriquez-Puertas, Maria de los A. Garcia-Garcia, Delia Porto-Gonzalez, Raul Gonzalez-Mugica, Dagmar García-Rivera, Belinda Sanchez-Ramirez, Rocmira Perez-Nicado, Guang-Wu Chen, Pedro Pablo Guerra-Chaviano, Luis Herrera Martinez, Mireida Rodriguez-Acosta, Arturo Chang-Monteagudo, Tays Hernandez-Garcia, Rolando Ochoa-Azze, Rinaldo Puga-Gomez, Luis Dairon Rodríguez-Prieto, Ivette Orosa-Vazquez, Laura Ruiz-Villegas, Yenisey Triana-Marrero, Enrique Noa-Romero, Beatriz Marcheco-Teruel, Consuelo Macías-Abraham, Laura M. Rodríguez-Noda
We evaluated response to a single dose of the FINLAY-FR-1A recombinant dimeric-RBD base vaccine during a phase I clinical trial with 30 COVID-19 convalescents, to test its capacity for boosting natural immunity. This short report shows: a) an excelle
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d49b54584eb53e0bda49ce6494529dce
https://doi.org/10.1101/2021.02.22.21252091
https://doi.org/10.1101/2021.02.22.21252091
Autor:
Delia Porto-Gonzalez, Dagmar García-Rivera, Laura M. Rodríguez-Noda, Marianniz Diaz-Hernandez, Yanet Climent-Ruiz, Vicente Verez-Bencomo, Mireida Rodriguez-Acosta, Enrique Noa-Romero, Belinda Sanchez-Ramirez, Arturo Chang-Monteagudo, Pedro Pablo Guerra-Chaviano, Rolando Ochoa-Azze, Carmen Valenzuela-Silva, Olivia Fernández-Medina, Anet Valdes-Zayas, Yanet Jerez-Barcelo, Tays Hernandez-Garcia, Rocmira Perez-Nicado, Beatriz Marcheco-Teruel, Yenisey Triana-Marrero, Guang-Wu Chen, Laura Ruiz-Villegas, Rinaldo Puga-Gomez, Luis Dairon Rodríguez-Prieto, Maria de los A. Garcia-Garcia, Consuelo Macías-Abraham, Yury Valdés-Balbín, Juliet Enriquez-Puertas, Ivette Orosa-Vazquez, Yaíma Zúñiga-Rosales, Luis Herrera-Martínez
Publikováno v:
The Lancet Regional Health. Americas, Vol 4, Iss, Pp 100079-(2021)
Lancet Regional Health. Americas
Lancet Regional Health. Americas
Background: As a first step towards a vaccine protecting COVID-19 convalescents from reinfection, we evaluated FINLAY-FR-1A vaccine in a clinical trial. Methods: Thirty COVID-19 convalescents aged 22-57 years were studied: convalescents of mild COVID
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::469c1a80321831634d0a584123ac6c00
https://doi.org/10.1016/j.lana.2021.100079
https://doi.org/10.1016/j.lana.2021.100079